English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  It has been suggested that inactivation of  p14  ARF , a tumor suppressor central to regulating p53 protein stability through interaction with the MDM2 oncoprotein, abrogates p53 activity in human tumors retaining the wild-type  TP53  gene. Differences in expression of tumor suppressor genes are frequently associated with cancer. We previously reported on a pattern of restricted p53 immunohistochemical overexpression significantly associated with microsatellite instability (MSI), low  TP53  mutation frequency, and MDM2 overexpression in colorectal cancers (CRCs). In this study, we investigated whether  p14  ARF  alterations could be a mechanism for disabling the p53 pathway in this subgroup of CRCs.    Results  Detailed maps of the alterations in the  p14  ARF  gene were determined in a cohort of 98 CRCs to detect both nucleotide and copy-number changes. Methylation-specific PCR combined with bisulfite sequencing was used to evaluate the prevalence and distribution of  p14  ARF  methylation.  p14  ARF  alterations were then correlated with MSI status,  TP53  mutations, and immunohistochemical expression of p53 and MDM2. The frequency of  p14  ARF  mutations was extremely low (1/98; 1%), whereas coexistence of methylated and unmethylated alleles in both tumors and normal colon mucosa was common (91/98; 93%). Only seven of ninety-eight tumors (7%) had a distinct pattern of methylation compared with normal colon mucosa. Evaluation of the prevalence and distribution of  p14  ARF  promoter methylation in a region containing 27 CpG sites in 35 patients showed a range of methylated CpG sites in tumors (0 to 25 (95% CI 1 to 13) versus 0 to 17 (95% CI 0 to 2)) in adjacent colon mucosa ( P  = 0.004). Hypermethylation of the  p14  ARF  promoter was significantly correlated with the restricted p53 overexpression pattern ( P  = 0.03), and MDM2 overexpression  (P  = 0.02), independently of MSI phenotype. Although no significant correlation between  p14  ARF  methylation and  TP53  mutational status was seen ( P  = 0.23), methylation involving the proximal CpG sites within the 5′ CpG flanking exon 1β was present more frequently in tumors with restricted p53 overexpression than in those with diffuse p53 overexpression (range of methylated clones 17 to 36% (95% CI 24 to 36%) versus range 0 to 3% (95% CI 0 to 3%),  P  = 0. 0003).    Conclusion   p14  ARF  epigenetic silencing may represent an important deregulating mechanism of the p53-MDM2-p14 ARF  pathway in CRCs exhibiting a restricted p53 overexpression pattern.

clinical epigenetics

RETRACTED ARTICLE: Hypermethylation of the 5′ CpG island of the p14ARF flanking exon 1β in human colorectal cancer displaying a restricted pattern of p53 overexpression concomitant with increased MDM2 expression